Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer

Research output: Contribution to journalComment/debatepeer-review

Fingerprint

Dive into the research topics of 'Prostate-specific antigen velocity (PSAV) risk count improves the specificity of screening for clinically significant prostate cancer'. Together they form a unique fingerprint.